BIOA
NASDAQ HealthcareBioAge Labs, Inc. - Common Stock
Drug Manufacturers - Specialty & Generic
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
๐ Market Data
| Price | $16.79 |
|---|---|
| Volume | 318,191 |
| Market Cap | 745.44M |
| RSI (14-Day) | 53.6 |
| 200-Day MA | $11.89 |
| 50-Day MA | $18.75 |
| 52-Week High | $24.00 |
| 52-Week Low | $3.67 |
| Forward P/E | -6.05 |
| Price / Book | 2.31 |
๐ฏ Investment Strategy Scores
BIOA scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Over-Hyped (44/100) โ this strategy Overbought stocks (potential short candidates).
Lowest fit among scored strategies: ๐ Moon Shot (11/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find BIOA in your text
Paste any article, transcript, or post โ the tool will extract BIOA and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-05-01.